DB
HOWL icon

Dmitry Balyasny’s Werewolf Therapeutics HOWL Stock Holding History

Dmitry Balyasny’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$644K Buy
+1,790,089
New +$1.09M ﹤0.01% 2417
2024
Q3 		– Sell
-10,459
Closed -$25.5K – 2917
2024
Q2 		$25.5K Sell
10,459
-12,589
-55% -$60.5K ﹤0.01% 2458
2024
Q1 		$149K Buy
+23,048
New +$134K ﹤0.01% 2458

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Dmitry Balyasny's HOWL Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Werewolf Therapeutics (HOWL) in Q2 2026: 1,790,089 shares worth $644K. The stake represents ﹤0.01% of the portfolio and ranks #2417 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in HOWL as recently as Q2 2024.

Dmitry Balyasny first reported a position in HOWL in Q1 2024 and has held it in 3 quarters since. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • Dmitry Balyasny held 1,790,089 shares of Werewolf Therapeutics worth $644K as of Q2 2026.
  • Werewolf Therapeutics was a new Dmitry Balyasny position in Q2 2026.
  • Werewolf Therapeutics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2417 holding.
  • Dmitry Balyasny first reported a position in Werewolf Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.